<DOC>
	<DOCNO>NCT01039636</DOCNO>
	<brief_summary>The purpose research study study safety increase dos FBS0701 , see quickly study medication absorbed quickly disappear bloodstream . FBS0701 new , oral iron chelator - medication take mouth increase body 's elimination iron . Iron chelators use patient develop iron overload transfusion . Four increase dos FBS0701 test study . The study start low dose give 4 patient ( 3 mg/kg/day . The next group 4 patient receive next high dose ( 8mg/kg/day result first 4 patient examine determined safe continue . Participating patient take study medication 7 day follow 28 day last dose determine reaction study medication - therefore total 35 day study . Patients need give 17 blood sample screen period first 15 day study ( total 9 tablespoon ) . Patients need stay overnight clinic need visit clinic 10 time screen on-study visit 35 day . Patients currently take iron chelator need stop treatment 22 day ( 5 day start study 15 day study ) . The result study helpful determine safety drug best dos FBS0701 use next study ass effectiveness new iron chelator .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Escalating Multiple Doses Iron Chelator Patients With Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>At least 18 year old Transfusion dependent ( least 8 transfusion per year ) transfusional iron overload need treatment deperoxamine , deferasirox deperiprone . Willing discontinue current iron chelation therapy 25 day prior enrollment total 3 week Willing fast midnight prior dose Serum ferritin great 400ng/ml Liver iron concentration great equal 1.5 mg iron . ( determined MRI SQUID within 12 month prior enrollment ) Cardiac iron great equal 12 millisecond ( determine MRI t2* within 18 month prior enrollment ) Mean last 3 pretransfusion hemoglobin value must great equal 7.5 g/dl Agrees use approve contraception Screening 30 day last administration study drug . Abstinence OK . Principal Investigator consider patient unfit study conduct medical review , physical examination screen assessment . Nonelective hospitalization past 30 day Evidence clinically relevant oral , cardiovascular , gastrointestinal , hepatic , renal , endocrine , pulmonary , neurologic , psychiatric skin disorder . Evidence significant renal insufficiency ; serum creatine upper limit normal proteinuria great 2 gm per day calculate creatinine clearance less equal 60ml/min Platelet count 150,000,000/ml and/or absolute neutrophil count le 1500/mm3 Alkaline phosphatase AST great 5 time upper limit normal ALT great 4 time upper limit normal Female patient pregnant lactate Use investigational agent within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Beta-thalassemia</keyword>
	<keyword>Sickle cell anemia</keyword>
	<keyword>Transfusional iron overload</keyword>
	<keyword>Iron overload</keyword>
	<keyword>Iron chelation</keyword>
</DOC>